Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Selection of anti-obesity drugs All FDA-approved anti-obesity medications indicated for chronic weight management were included: GLP-1 receptor agonists: liraglutide (Saxenda), semaglutide (Wegovy) Dual GLP-1/GIP receptor agonist: tirzepatide (Zepbound) Non-GLP-1 combinations: naltrexone/bupropion (Contrave) and phentermine/topiramate (Qsymia) Setmelanotide (Imcivree) was excluded due to its orphan indication for genetic obesity syndromes, which involves a distinct patient population and safety profile
Frequently Asked Questions Have questions before you get started
Always follow the instructions provided by your healthcare provider or the medication leaflet for safe administration
The data, published in The Lancet and presented virtually on Saturday at the annual meeting of the American Diabetes Association, come from one of five phase 3 studies that will support an FDA submission for tirzepatide by the end of the year
While C peptide reflects the -cell secretory capacity, its hepatic extraction, unlike that of insulin, is negligible (43, 44)
Overall, more research will be necessary to see what the right move is, and potentially even develop an SSRI that works better alongside GLP-1 drugs like semaglutide
